Kosakai N, Igari J, Kumamoto Y, Sakai S, Nishio A, Nagai T, Shigeta S, Shiraiwa Y, Abe K, Tazaki H, Iri H, Uchida H, Ando Y, Furuya H, Matsuda S, Soeda N, Yokomatsu M, Oguri T, Furusawa T, Takeuchi Y, Tsuchida H, Yamashita N, Okamoto Y, Shimoe S, Kamiki T, Nasu M, Yamaguchi K
Jpn J Antibiot. 1982 Apr;35(4):1022-44.
In vitro activities of antibacterial agents against E. coli, Klebsiella, Citrobacter and Proteus which were isolated from patients urinary tract infections at 8 hospitals in Japan, were investigated by agar dilution method from July to October in 1979. The summarized results are as follows. 1. Among oral antibacterial agents, MPC and PPA have showed potent antibacterial activities against E. coli and Klebsiella. Among parenteral antibiotics, CTM was the most active against E. coli and Klebsiella. However, ABPC-resistant E. coli and Klebsiella have appeared to occupy about 40% and 96% of bacteria isolated from urinary tract infections, respectively. 2. In vitro activities of antibacterial agents against Proteus and Citrobacter showed not so potent. 3. Causative organisms in female patients with simple urinary tract infections were mainly E. coli and Klebsiella. 4. Among oral antibacterial agents, PPA have shown similar antimicrobial activities against E. coli isolated from simple and complicated urinary tract infections. ABPC and MPC have been influenced in some degree by these factors. However, parenteral antibiotics are not influenced by these factors. On the other hand, in vitro activities of antibacterial agents against Klebsiella isolated from simple and complicated urinary tract infections were similar.
1979年7月至10月，采用琼脂稀释法对从日本8家医院的患者尿路感染中分离出的大肠杆菌、克雷伯菌、柠檬酸杆菌和变形杆菌进行了抗菌剂的体外活性研究。总结结果如下。1. 在口服抗菌剂中，MPC和PPA对大肠杆菌和克雷伯菌显示出较强的抗菌活性。在注射用抗生素中，CTM对大肠杆菌和克雷伯菌的活性最强。然而，耐ABPC的大肠杆菌和克雷伯菌分别占从尿路感染中分离出的细菌的约40%和96%。2. 抗菌剂对变形杆菌和柠檬酸杆菌的体外活性不强。3. 单纯性尿路感染女性患者的病原体主要是大肠杆菌和克雷伯菌。4. 在口服抗菌剂中，PPA对从单纯性和复杂性尿路感染中分离出的大肠杆菌显示出相似的抗菌活性。ABPC和MPC在一定程度上受这些因素影响。然而，注射用抗生素不受这些因素影响。另一方面，抗菌剂对从单纯性和复杂性尿路感染中分离出的克雷伯菌的体外活性相似。
